Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–95 of 95 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Inactive comparator Clear all
Completed Phase 2Phase 3 Interventional Results available

Augmenting Language Therapy for Aphasia: Levodopa

NCT01429077
View directory record Official record
Conditions
Nonfluent Aphasia, Stroke
Interventions
levodopa/carbidopa, Placebo comparator
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
21 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 25, 2013 · Synced Oct 21, 2026, 10:26 PM EDT
Completed Phase 4 Interventional Results available

Clinical and Imaging Trial of Uridine for Veterans With Suicidal Ideation

NCT03265964
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Uridine, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 21, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)

NCT05894564
View directory record Official record
Conditions
Covid19
Interventions
Fluvoxamine, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
103
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 21, 2026, 10:26 PM EDT
Completed Phase 2 Interventional Results available

A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer

NCT02499497
View directory record Official record
Conditions
Prostate Cancer
Interventions
LY2452473, Placebo
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
19 Years and older · Male only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Gainesville, Florida • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 21, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

NCT02836873
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
20 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Fresno, California • La Palma, California • Lincoln, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 21, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Results available

Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection

NCT01069900
View directory record Official record
Conditions
Intraabdominal Infections
Interventions
Moxifloxacin (Avelox, BAY12-8039), Ertapenem, Amoxicillin/Clavulanate, Moxifloxacin placebo, Ertapenem placebo, Amoxicillin/Clavulanate placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
3 Months to 17 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
San Diego, California • Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Oct 21, 2026, 10:26 PM EDT
Withdrawn Phase 2 Interventional

Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome

NCT05198362
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Placebo, Tesomet
Other · Drug
Lead sponsor
Saniona
Industry
Eligibility
13 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 21, 2026, 10:26 PM EDT
Terminated Phase 4 Interventional Results available

Sinusitis and Facial Pain Disorders Anti-Depression Trial

NCT00754793
View directory record Official record
Conditions
Chronic Sinusitis, Facial Pain Disorder, Depression
Interventions
escitalopram, placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 21, 2026, 10:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of AL-53817 Nasal Spray Solution

NCT01454505
View directory record Official record
Conditions
Nasal Allergies, Allergies
Interventions
AL-53817 nasal spray solution, Vehicle nasal spray
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Oct 21, 2026, 10:26 PM EDT
Completed Early Phase 1 Interventional Results available

Progesterone for Cannabis Withdrawal

NCT03430050
View directory record Official record
Conditions
Cannabis Use Disorder, Cannabis Withdrawal
Interventions
Progesterone, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Oct 21, 2026, 10:26 PM EDT
Not listed Phase 2 Interventional

Biological Effects of Quercetin in COPD Phase II

NCT06003270
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Emphysema, Chronic Bronchitis With Airway Obstruction
Interventions
Quercetin 1000 mg, Quercetin 500 MG, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 21, 2026, 10:26 PM EDT
Completed No phase listed Observational

Relationship Between Eye Pressure and Ganglion Cell Function in Eyes Receiving Latanoprost Versus Placebo

NCT01042665
View directory record Official record
Conditions
Glaucoma
Interventions
latanoprost 0.005%, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 85 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Palm Beach Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Mar 28, 2014 · Synced Oct 21, 2026, 10:26 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of XT-150 in Osteoarthritis of the Knee

NCT04124042
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
XT-150, Placebo
Biological · Drug
Lead sponsor
Xalud Therapeutics, Inc.
Industry
Eligibility
45 Years to 85 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
La Mesa, California • Napa, California • Santa Monica, California + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 21, 2026, 10:26 PM EDT
Completed Phase 2 Interventional Results available

LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration

NCT02355028
View directory record Official record
Conditions
Exudative Age-Related Macular Degeneration
Interventions
LHA510 ophthalmic suspension, LHA510 vehicle, Ranibizumab ophthalmic solution
Drug
Lead sponsor
Alcon, a Novartis Company
Industry
Eligibility
50 Years to 90 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 21, 2026, 10:26 PM EDT
Completed Not applicable Interventional Results available

RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms

NCT05965752
View directory record Official record
Conditions
Long COVID, Long COVID-19, Long COVID19
Interventions
BrainHQ/Active Comparator Activity, BrainHQ, PASC CoRE, tDCS-active, tDCS-sham
Other · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 21, 2026, 10:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effects of Smoked Marijuana on Risk Taking and Decision Making Tasks

NCT00373399
View directory record Official record
Conditions
Marijuana Use Disorder
Interventions
Inactive Marijuana (0% THC), Low THC marijuana (1.8 %THC), High THC marijuana (3.9% THC)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 21, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine)

NCT05890586
View directory record Official record
Conditions
Covid19
Interventions
Fluvoxamine, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
91
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 21, 2026, 10:26 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of CES in New Mothers During the Post Partum Period

NCT03210155
View directory record Official record
Conditions
Anxiety, Depression, Insomnia, Sleep Quality
Interventions
Alpha-Stim AID CES (Active Comparator), Alpha-Stim AID CES (Sham Comparator)
Device
Lead sponsor
Christina Murphey, RN, PhD
Individual
Eligibility
18 Years to 45 Years · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Austin, Texas • Corpus Christi, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 21, 2026, 10:26 PM EDT
Completed Phase 3 Interventional

Ropivacaine 0.2% Pre-Filled Dispenser for the Treatment of Postsurgical Pain in Patients Undergoing Cesarean Delivery

NCT02959476
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Ropivacaine, Placebos
Drug
Lead sponsor
BioQ Pharma, Inc.
Industry
Eligibility
Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • Sheffield, Alabama • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 21, 2026, 10:26 PM EDT
Completed Phase 2 Interventional

Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients

NCT06249152
View directory record Official record
Conditions
Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma
Interventions
QLS-111, 0.015%, QLS-111, 0.030%, QLS-111, 0.075%, QLS-111 vehicle ophthalmic solution
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 21, 2026, 10:26 PM EDT
Completed Not applicable Interventional

The Effect of Vitamin D Supplementation on Glucose Metabolism in Non-Diabetic African American Adults

NCT01141192
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
vitamin D3, cholecalciferol, Inactive comparator
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
19 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Oct 21, 2026, 10:26 PM EDT
Active, not recruiting Phase 2 Interventional

Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT05510115
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 21, 2026, 10:26 PM EDT
Completed Phase 2 Interventional

Lovastatin as a Potential Modulator of Apoptosis in Chronic Obstructive Pulmonary Disease (COPD)

NCT00700921
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Lovastatin, Placebo
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
45 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 21, 2026, 10:26 PM EDT